首页> 外文期刊>Antimicrobial agents and chemotherapy. >Escherichia coli ATCC 35218 as a quality control isolate for susceptibility testing of Haemophilus influenzae with haemophilus test medium.
【24h】

Escherichia coli ATCC 35218 as a quality control isolate for susceptibility testing of Haemophilus influenzae with haemophilus test medium.

机译:大肠杆菌ATCC 35218作为质量控制分离株,用于使用嗜血杆菌检测培养基对流感嗜血杆菌进行药敏试验。

获取原文
获取原文并翻译 | 示例
           

摘要

Current National Committee for Clinical Laboratory Standards (NCCLS) susceptibility guidelines for quality control testing with Haemophilus influenzae do not include a beta-lactamase-producing strain that could detect the deterioration of the beta-lactamase inhibitor components of amoxicillin-clavulanic acid, ampicillin-sulbactam, and piperacillin-tazobactam. The objective of the study was to determine if comparable quality control results for Escherichia coli ATCC 35218, a beta-lactamase-producing strain, would be produced for the three beta-lactam-beta-lactamase inhibitor agents with Haemophilus test medium and Mueller-Hinton medium. The criteria used in this study to determine if Haemophilus test medium was acceptable for quality control testing of E. coli ATCC 35218 was that 100% of the results obtained with an antimicrobial agent-methodology combination needed to be within the acceptable NCCLS ranges established with Mueller-Hinton medium. The MIC testing results obtained by the broth microdilution and E-test methods with amoxicillin-clavulanic acid and piperacillin-tazobactam were all within the NCCLS ranges; however, the results obtained with ampicillin-sulbactam by both methods were not within the NCCLS ranges. Acceptable results were obtained by the disk diffusion methodology with ampicillin-sulbactam and piperacillin-tazobactam but not with amoxicillin-clavulanic acid. When performing susceptibility testing with H. influenzae with the beta-lactam-beta-lactamase inhibitors, in addition to quality control testing with H. influenzae ATCC 49247, testing of E. coli ATCC 35218 on Haemophilus test medium is an effective way to monitor the beta-lactamase inhibitors in some antimicrobial agent-methodology combinations.
机译:当前的国家临床实验室标准委员会(NCCLS)流感嗜血杆菌质量控制测试敏感性指南不包括可检测阿莫西林-克拉维酸,氨苄青霉素-舒巴坦的β-内酰胺酶抑制剂成分劣化的产生β-内酰胺酶的菌株和哌拉西林-他唑巴坦。这项研究的目的是确定是否可以使用嗜血杆菌属检测培养基和Mueller-Hinton对三种β-内酰胺酶-β-内酰胺酶抑制剂进行生产,产生大肠杆菌β-内酰胺酶的大肠杆菌ATCC 35218的可比质量控制结果中。本研究用于确定嗜血杆菌测试培养基是否可用于大肠杆菌ATCC 35218的质量控制测试的标准是,使用抗菌剂-方法组合获得的结果的100%必须在Mueller建立的可接受的NCCLS范围内-Hinton培养基。用阿莫西林-克拉维酸和哌拉西林-他唑巴坦通过肉汤微量稀释和E-test方法获得的MIC测试结果均在NCCLS范围内;但是,两种方法用氨苄西林舒巴坦获得的结果均不在NCCLS范围内。通过盘扩散方法,使用氨苄西林-舒巴坦和哌拉西林-他唑巴坦,但不使用阿莫西林-克拉维酸,可获得可接受的结果。当使用β-内酰胺-β-内酰胺酶抑制剂对流感嗜血杆菌进行药敏测试时,除了使用流感嗜血杆菌ATCC 49247进行质量控制测试外,在嗜血杆菌测试培养基上测试大肠杆菌ATCC 35218是监测流感嗜血杆菌的有效方法。 β-内酰胺酶抑制剂在某些抗菌剂-方法学组合中的应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号